---
title: "Pfizer climbs 3% as Q3 results beat estimates and guidance raised"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304295294.md"
description: "Pfizer rose 2.57% to $30.77 as Q3 revenue beat estimates and full-year EPS guidance was raised to $2.95–$3.05."
datetime: "2026-11-04T14:33:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304295294.md)
  - [en](https://longbridge.com/en/news/304295294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304295294.md)
generator: "portal-rs"
---

# Pfizer climbs 3% as Q3 results beat estimates and guidance raised

Pfizer (PFE.US) climbed nearly **3%** during regular trading to **$30.77**.

The pharmaceuticals industry index rose 2.4% over the same period.

The company reported fiscal third-quarter revenue of **$16.58 billion**, topping the analyst consensus of **$15.87 billion**. Adjusted earnings per share came in at **$0.87**, beating estimates of **$0.73**. Operational revenue grew 7% excluding Covid-19 products, while sales from launched and acquired non-Covid assets surged 32%. Pfizer raised its full-year revenue guidance to **$62.0 billion to $64.0 billion** and adjusted EPS outlook to **$2.95 to $3.05**, up from prior ranges of $60.5 billion to $62.5 billion and $2.80 to $3.00, respectively.

Citi raised its price target on Pfizer to $30 from $27, while RBC increased its target to $28 from $25. Management said on the earnings call that cost savings will be reinvested into R&D with a focus on oncology and obesity pipelines, targeting approval for a monthly weight-loss injection by 2028. Nearly all of the expected $7.2 billion in net savings are on track to be realized by end-2026.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md)
- [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md)
- [This Insider Has Just Sold Shares In Tempus AI](https://longbridge.com/en/news/306369536.md)
- [Nasdaq (NDAQ) Just Gave Investors Something To Think About](https://longbridge.com/en/news/306370324.md)
- [Anthropic PBC (ANT) Claims Claude Solved The 167 Year Old Riemann Hypothesis](https://longbridge.com/en/news/306374461.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**